Skip to main content
    F

    Foghorn Therapeutics Inc (FHTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.83
    +0.04 (+2.23%)

    Market Cap: $124.12M

    Last updated: Nov 17, 2026 at 4:26 PM ET

    Foghorn Therapeutics Inc (FHTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Foghorn Therapeutics (FHTX) has a market cap of $124.12M and an enterprise value of $43.82M. Revenue grew 357.33% over the last 12 months from the 12 months before. Its share count is up 13.38% from a year earlier.

    Total Valuation

    Enterprise value is 64.70% below the market cap, as cash exceeds debt.

    Market Cap$124.12M
    Enterprise Value$43.82M
    Latest price (Nov 17, 2026)$1.83

    Key Dates

    The next earnings report is expected on Mar 9, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 9, 2027 (expected)
    Last Earnings DateNov 9, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.18% in the quarter ended Sep 30, 2026 and grew 6.84% a year over 2 years.

    Shares Outstanding71.46M
    Shares Change (YoY)+13.38%
    Shares Change (QoQ)+1.18%
    Share Count Growth (2Y CAGR)+6.84%

    Valuation Ratios

    The price to sales ratio is 1.2x.

    P/E Ratio41.0x
    P/S Ratio1.2x
    Forward P/S1.2x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 21.1x EBITDA.

    EV / Earnings4.7x
    EV / Sales0.4x
    EV / EBITDA21.1x

    Price Statistics

    The stock is down 60.98% over 52 weeks and trades 31.20% below its 50-day average.

    Beta (1Y)1.75
    52-Week Change-60.98%
    1-Month Change-2.14%
    3-Month Change-74.08%
    6-Month Change-49.17%
    5-Year Change-83.61%
    Total Return (1Y)-60.98%
    Total Return (3Y CAGR)-24.54%
    Total Return (5Y CAGR)-33.12%
    Return vs SPY (1Y)-75.10%
    Max Drawdown (1Y)-74.68%
    Max Drawdown (3Y)-82.08%
    Sharpe Ratio (1Y)-1.21
    Correlation with SPY (1Y)0.29
    50-Day Average$2.66
    200-Day Average$4.47
    52-Week Range$1.76 to $7.61
    RSI (14 Days)35.4
    Average Volume (20 Days)749.84K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.24x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio4.24x
    Quick Ratio4.24x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on Assets (ROA)4.93%
    ROA (5Y Average)-29.76%
    ROIC (5Y Average)60.45%
    Asset Turnover0.57x

    Scores

    FHTX has an Altman Z-Score of -2.63, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score-2.63
    Altman Z ZoneDistress
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $112.13M over the last 12 months.

    Revenue$112.13M
    Revenue Growth (YoY)+357.33%
    Gross Profit$112.13M
    Operating Income$2.38M
    Pretax Income$9.42M
    Net Income$9.42M
    Reported EPS (TTM)$0.04

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$80.30M
    Total Debt$0
    Net Cash$80.30M
    Net Cash Per Share$1.12
    Working Capital$121.00M
    Shareholder Equity-$14.08M
    Total Assets$190.95M
    Total Liabilities$205.04M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $57.00K of capital spending, operating cash flow left -$83.68M of free cash flow.

    Operating Cash Flow-$83.62M
    Capital Expenditures$57.00K
    Free Cash Flow-$83.68M
    FCF Per Share-$1.41
    Depreciation and Amortization$3.40M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 2.13%.

    Gross Margin100.00%
    Operating Margin2.13%
    Pretax Margin8.40%
    Net Margin8.40%
    FCF Margin-74.63%

    Growth

    Revenue grew 17.14% a year over 3 years.

    Revenue Growth (3Y CAGR)+17.14%
    Revenue Growth (5Y CAGR)+135.14%

    Revenue and profit by year

    Dividends and Yields

    FHTX does not pay a dividend.

    Earnings Yield2.44%
    Buyback Yield-42.81%
    Shareholder Yield-42.81%

    Peer Position

    Against 8 similar companies, FHTX has the 7th highest P/S.

    P/S Ratio1.2x vs 3.5x median
    Revenue Growth (Trailing 4 Quarters, YoY)+357.33% vs -31.54% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -55.07% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-55.07%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About FHTX

    What is FHTX's market cap?

    Foghorn Therapeutics has a market cap of $124.12M. Its enterprise value, which adds debt and subtracts cash, is $43.82M.

    What is FHTX's P/E ratio?

    Foghorn Therapeutics has a trailing P/E ratio of 41.0x.

    How many shares of FHTX are outstanding?

    Foghorn Therapeutics has 71.46M shares outstanding. The count is up 13.38% from a year earlier.

    Does FHTX pay a dividend?

    No. Foghorn Therapeutics does not pay a dividend.

    How much debt does FHTX have?

    Foghorn Therapeutics has $0 of total debt and $80.30M of cash and equivalents, a net cash position of $80.30M.